Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

to rapid approval in hypercalcemia. We also foresee the potential for subsequent approvals in other diseases, such as non-Hodgkin's lymphoma, bone metastases, Paget's disease, and osteoporosis. Genta plans to manage the G4544 development program in oncology, and we intend to seek a partner for clinical programs in metabolic bone disease."

Gallium-Containing Compounds

G4544 is one of a class of gallium-containing compounds that were originally developed by the U.S. National Cancer Institute. In investigational studies, high doses of gallium nitrate demonstrated consistent antitumor activity in patients with non-Hodgkin's lymphoma. However, experimental work by Genta personnel and others established that lower doses of gallium directly inhibited calcium release from bone, principally by decreasing bone resorption and possibly by also stimulating bone formation.

Many diseases are associated with accelerated bone loss, including osteoporosis, cancer, and Paget's disease. In some diseases, the rate of loss is slow and subtle, while in others the rate is rapid and acutely life- threatening. In osteoporosis, the most prevalent bone-losing condition, the process of bone loss extends over many years before the disease becomes evident. Conversely, in cancer-related hypercalcemia, bone loss is so rapid that it overwhelms the kidney's ability to eliminate calcium from the blood, and this condition can quickly become lethal. In patients with cancer-related hypercalcemia who were resistant to hydration, randomized double-blind trials have been conducted with Ganite compared with calcitonin and with two bisphosphonates (etidronate [Didronel(R); Proctor and Gamble] and pamidronate [Aredia(R); Novartis, Inc.]).

About G4544

G4544 was developed to enable extended administration of the active ingredient in Ganite, which may greatly improve patient convenience and avoid the current need for intravenous pumps or hospitalization. The initial focus of clinica
'/>"/>

SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Pulse Light Clinic in ... sufferers as part of their ongoing research into the condition. ... for their Rosacea. The survey participants were aged between 20 ... 53% women. The results revealed some rather surprising ... or attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... sufferers that chronic Lyme doesn,t exist; no viable alternative explanations given ... BETHESDA, Md. , ... Connecticut Attorney General, and nine months of review, the Infectious Diseases ... disease treatment guidelines with a status quo decision critics call "highly suspect." ...
... JAMESBURG, N.J. , April 28 Phytomedics Inc., a clinical ... solely derived from plant sources, today announced that Dr. Laurie Smaldone ... at the BIO 2010 International Convention on Thursday, May 6th , ... , , ...
Cached Medicine Technology:Judge, Jury = Status Quo: Astonishment as Medical Panel Rubber Stamps its Own Controversial Guidelines 2Judge, Jury = Status Quo: Astonishment as Medical Panel Rubber Stamps its Own Controversial Guidelines 3Phytomedics Inc. To Present at BIO 2010 International Convention 2
(Date:6/30/2015)... ... June 30, 2015 , ... NJ Top Dentist, Dr. Susan Goldfarb, had ... a CPR Course for members of the Bergen County Dental Society. She does ... latest CPR recommendations for Healthcare Providers. Life Support from Hackensack Hospital provided the ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... imaging. The company provides high quality record management services for patient records. Medical ... is normally required by physicians and clinics. , With the increase in ...
(Date:6/30/2015)... ... June 30, 2015 , ... Eldermark Software ... Notify™, for the senior care sector. As an innovator of senior care ... to become more efficient and offer residents better care. , This next-generation interactive ...
(Date:6/30/2015)... ... June 30, 2015 , ... Harbor Village Detox ... addiction care in Florida on June 12th. Holly Vasquez-Cortella was recently quoted as ... a website dedicated to reporting on trending addiction news and treatment innovations. The article ...
(Date:6/30/2015)... ... June 30, 2015 , ... Nuretix Research, creators ... Knockout Zone Miami (KO Zone), a state-of-the-art training facility owned by ... Diego de Vera. The partnership will provide KO Zone clients and athletes with ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 2Health News:NJ Top Dentists Presents, Dr. Susan Goldfarb of Advanced Periodontics & Implant Care! 3Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3
... is available in French . Montreal -- ... times more likely to develop respiratory or gastrointestinal infections in the ... a Centre d,Hbergement de Soins de Longue Dure (CHLSD). These are ... Canadian Medical Association Journal today. "There certainly seems to ...
... both breast cancers and leukemias, according to two reports published ... Medicine ( http://www.jem.org ). The single protein is ... in the cell. , A team led by Ute Moll ... HSP90 activity rendered normally protected proteins vulnerable to attack and ...
... mothers have garnered accolades for rescuing skinned knees on ... lullabies. Now they,re gaining merit for their offspring,s physical ... published in the journal Psychological Science , Brandeis ... the University of British Columbia and the University of ...
... , MONDAY, Jan. 23 (HealthDay News) -- ... increased risk for respiratory or gastrointestinal infections if they ... or spring, according to a new study. Canadian ... care facilities in Toronto, Ontario, and Montreal and Riviere-du-Loup, ...
... International Conference on Cell Therapy for Cardiovascular Disease ... a comprehensive program dedicated to the evolving field ... of cardiac and vascular disease, as well as ... year,s conference will focus on preclinical and clinical ...
... You could call it paying it forward. A trip to ... what if the information documented as a result of your ... few provinces away? Terry Klassen and his research team ... Canada (PERC) have done just that and the impact of ...
Cached Medicine News:Health News:Emergency room visits risky for elderly residents from long-term care facilities 2Health News:Nurturing mothers rear physically healthier adults 2Health News:Nurturing mothers rear physically healthier adults 3Health News:Certain Seniors at Risk for Infection After ER Visit: Study 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 2Health News:Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC 3Health News:Pediatric emergency research team hit the mark 2
... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
Medicine Products: